Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop
cancer cells from dividing so they stop growing or die. Bevacizumab may stop the growth of
cancer by stopping blood flow to the leukemic cells in the bone marrow. Giving idarubicin and
cytarabine with bevacizumab may kill more cancer cells. It is not yet know whether giving
idarubicin together with cytarabine is more effective with or without bevacizumab in treating
acute myeloid leukemia. This randomized phase II trial is studying how well giving idarubicin
and cytarabine together with bevacizumab works compared to idarubicin and cytarabine alone in
treating patients with newly diagnosed acute myeloid leukemia